Examining the Role of Hope in PrEP Willingness, Adherence, and Persistence Among Young African Women

Waru Gichane, PhD, MSPH
University of California San Francisco
HPTN Annual Meeting June 3-7, 2013
Key Takeaways

• Hope was associated with PrEP willingness, but not adherence and persistence

• Further investigation is needed to understand how hope may be incorporated into prevention interventions
• One in five new HIV diagnoses in Sub-Saharan Africa occur among adolescent girls and young women (AGYW) ages 15-24 years old.

• Studies in Eastern and Southern Africa indicate that AGYW report suboptimal PrEP adherence and persistence.

• Hope is associated with some protective sexual behaviors and ART adherence, but the relationship between hope and PrEP use has not been explored.
Hope and HIV Prevention

Fig. 1. The relationship between hope and HIV prevention.

Bernay, Rhodes, & Barnett, AIDS, 2007
To examine the relationship between hope and PrEP **willingness**

To examine the relationship between hope and PrEP **adherence**

To examine the relationship between hope and PrEP **persistence**
HPTN 082

- Study Design: A Phase IV randomized multi-site prospective study to assess PrEP acceptance and adherence among HIV-uninfected young women.

- Population: 451 Young women ages 16-25 years

- Study countries: Zimbabwe and South Africa

- Study arms: Enhanced adherence counseling based on observed drug levels (treatment) vs. Standard adherence counseling (control)

- Main outcomes:
  - 95% PrEP uptake
  - DBS confirmed detectable PrEP at month 3 (84%), month 6 (57%), and month 12 (31%)
  - 4 seroconversions
**Methods/Analysis Plan**

**Independent variable:** Hope for the future: 6 items, Likert scale, Range: 6-24

**Outcome variables:**
- **Aim 1:** PrEP willingness: 7 items, Likert scale, Range: 6-30
- **Aim 2:** PrEP adherence: Dichotomous (high adherence= TFV-DP ≥700 fmol/punch, detectable= TFV-DP ≥16 fmol/punch)
- **Aim 3:** PrEP persistence: Dichotomous (high adherence at months 3 and 6)

**Control variables:** site, study arm

**Analyses:**
- **Aim 1:** Linear regression to examine the relationship between baseline hope and PrEP willingness
- **Aim 2:** Generalized estimating equations (GEE) to examine association between baseline hope and PrEP adherence at months 3, 6, and 12
- **Aim 3:** Logistic regression to examine the association between hope and PrEP persistence
## Results

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall (n=451)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>21 (19, 22)</td>
</tr>
<tr>
<td><strong>Education</strong></td>
<td></td>
</tr>
<tr>
<td>Primary</td>
<td>9 (2%)</td>
</tr>
<tr>
<td>Secondary</td>
<td>388 (86%)</td>
</tr>
<tr>
<td>College or University</td>
<td>54 (12%)</td>
</tr>
<tr>
<td><strong>Study Site</strong></td>
<td></td>
</tr>
<tr>
<td>Cape Town, South Africa</td>
<td>141 (31%)</td>
</tr>
<tr>
<td>Johannesburg, South Africa</td>
<td>162 (36%)</td>
</tr>
<tr>
<td>Harare, Zimbabwe</td>
<td>148 (33%)</td>
</tr>
</tbody>
</table>
At baseline hope was positively associated with PrEP willingness ($\beta=0.62$, 95% CI: 0.50, 0.75)
Hope was not significantly associated with high PrEP adherence (aRR=0.98, 95% CI: 0.94, 1.01) at follow-up.

Hope was not significantly associated with detectable PrEP adherence (aRR=0.99, 95% CI: 0.98, 1.01) at follow-up.
Results: PrEP persistence

Hope was not significantly associated with PrEP persistence (aOR=0.96, 95% CI: 0.90, 1.02).
Implications/Future Considerations

• Hope is associated with PrEP willingness, but not PrEP adherence or persistence

• Incorporating hope building into PrEP programs may increase willingness to use PrEP

• Further research may be needed to disentangle the relationship between hope and PrEP adherence and persistence
Acknowledgments

• Overall support for the HIV Prevention Trials Network (HPTN) is provided by the National Institute of Allergy and Infectious Diseases (NIAID), Office of the Director (OD), National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under Award Numbers UM1AI068619-17 (HPTN Leadership and Operations Center), UM1AI068617-17 (HPTN Statistical and Data Management Center), and UM1AI068613-17 (HPTN Laboratory Center).

• The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.